Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non Operating Income (2023 - 2025)

Historic Non Operating Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $2.7 million.

  • Monte Rosa Therapeutics' Non Operating Income fell 80.32% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 3478.04%. This contributed to the annual value of $11.0 million for FY2024, which is 3236.11% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Non Operating Income of $2.7 million as of Q3 2025, which was down 80.32% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Non Operating Income peaked at $4.5 million during Q2 2025, and registered a low of $1.6 million during Q4 2023.
  • For the 3-year period, Monte Rosa Therapeutics' Non Operating Income averaged around $2.7 million, with its median value being $2.6 million (2024).
  • The largest annual percentage gain for Monte Rosa Therapeutics' Non Operating Income in the last 5 years was 7252.32% (2025), contrasted with its biggest fall of 80.32% (2025).
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Non Operating Income stood at $1.6 million in 2023, then skyrocketed by 63.44% to $2.6 million in 2024, then grew by 4.62% to $2.7 million in 2025.
  • Its Non Operating Income stands at $2.7 million for Q3 2025, versus $4.5 million for Q2 2025 and $3.7 million for Q1 2025.